The role of the sphingosine axis in immune regulation: A dichotomy in the anti-inflammatory effects between sphingosine kinase 1 and sphingosine kinase 2-dependent pathways

Background: Sphingosine kinase has been identified as playing a central role in the immune cascade, being a common mediator in the cellular response to a variety of signals. The different effects of sphingosine kinase 1 and 2 (SphK1 and SphK2, respectively) activity have not been completely characterized. Aim: To determine the different roles played by SphK1 and SphK2 in the regulation of immune-mediated disorders. Methods: Nine groups of mice were studied. Concanavalin A (ConA) injection was used to induce immune-mediated hepatitis. Mice were treated with SphK1 inhibitor (termed SphK-I) and SphK2 inhibitor (termed ABC294640), prior to ConA injection, and effects of treatment on liver enzymes, subsets of T lymphocytes, and serum levels of cytokines were observed. Results: While liver enzyme elevation was ameliorated by administration of SphK1 inhibitor, SphK2 inhibitor-treated mice did not show this tendency. A marked decrease in expression of CD25+ T-cells and Foxp+ T-cells was observed in mice treated with a high dose of SphK1 inhibitor. Alleviation of liver damage was associated with a statistically significant reduction of serum IFNγ levels in mice treated with SphK1 inhibitor and not in those treated with SphK2 inhibitor. Conclusions: Early administration of SphK1 inhibitor in a murine model of immune-mediated hepatitis alleviated liver damage and inflammation with a statistically significant reduction in IFN-γ levels. The data support a dichotomy in the anti-inflammatory effects of SphK1 and SphK2, and suggests that isoenzyme-directed therapies can improve the effect of targeting these pathways.

[1]  J. Walia,et al.  A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis , 2021, International journal of molecular sciences.

[2]  S. Spiegel,et al.  Deletion or inhibition of SphK1 mitigates fulminant hepatic failure by suppressing TNFα‐dependent inflammation and apoptosis , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Y. Ilan,et al.  The Role of Sphingolipid Pathway in Liver Fibrosis: An Emerging New Potential Target for Novel Therapies. , 2020, American journal of physiology. Cell physiology.

[4]  Hailei Mao,et al.  Inhibition of Sphingosine Kinase 1 Attenuates Sepsis-induced Microvascular Leakage via Inhibiting Macrophage NLRP3 Inflammasome Activation in Mice , 2020, Anesthesiology.

[5]  A. Bishayee,et al.  Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. , 2019, Pharmacology & therapeutics.

[6]  Ke Xu,et al.  Roles of sphingosine-1-phosphate signaling in cancer , 2019, Cancer Cell International.

[7]  C. Sassoli,et al.  Sphingosine 1-Phosphate (S1P)/ S1P Receptor Signaling and Mechanotransduction: Implications for Intrinsic Tissue Repair/Regeneration , 2019, International journal of molecular sciences.

[8]  J. Schneider-Schaulies,et al.  Translational Approaches Targeting Ceramide Generation From Sphingomyelin in T Cells to Modulate Immunity in Humans , 2019, Front. Immunol..

[9]  Chunping Jiang,et al.  Sphingosine kinase 1 knockout alleviates hepatic ischemia/reperfusion injury by attenuating inflammation and oxidative stress in mice. , 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.

[10]  Y. Ilan.  β-Glycosphingolipids as Mediators of Both Inflammation and Immune Tolerance: A Manifestation of Randomness in Biological Systems , 2019, Front. Immunol..

[11]  S. Spiegel,et al.  Examination of the role of sphingosine kinase 2 in a murine model of systemic lupus erythematosus , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Xiuping Chen,et al.  The sphingosine kinase‐1/sphingosine‐1‐phosphate axis in cancer: Potential target for anticancer therapy , 2019, Pharmacology & therapeutics.

[13]  M. Zeng,et al.  The Role of S1P and the Related Signaling Pathway in the Development of Tissue Fibrosis , 2019, Front. Pharmacol..

[14]  Y. Ilan.  Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track , 2018, Journal of leukocyte biology.

[15]  Naser Safaie,et al.  The role of sphingosine 1 phosphate in coronary artery disease and ischemia reperfusion injury , 2018, Journal of cellular physiology.

[16]  K. Sakimura,et al.  The role of sphingosine‐1‐phosphate in inflammation and cancer progression , 2018, Cancer science.

[17]  D. Winter,et al.  Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling , 2018, Front. Immunol..

[18]  K. Sakimura,et al.  Different Roles of Sphingosine Kinase 1 and 2 in Pancreatic Cancer Progression. , 2018, The Journal of surgical research.

[19]  K. Sakimura,et al.  Targeting the SphK1/S1P/S1PR1 Axis That Links Obesity, Chronic Inflammation, and Breast Cancer Metastasis. , 2018, Cancer research.

[20]  B. Kleuser.  Divergent Role of Sphingosine 1-Phosphate in Liver Health and Disease , 2018, International journal of molecular sciences.

[21]  Yusuf A. Hannun,et al.  Sphingolipids and their metabolism in physiology and disease , 2017, Nature Reviews Molecular Cell Biology.

[22]  A. Huwiler,et al.  The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. , 2017, Pharmacology & therapeutics.

[23]  M. Maceyka,et al.  Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology , 2017, Critical reviews in biochemistry and molecular biology.

[24]  I. Raz,et al.  Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. , 2017, Journal of medicinal food.

[25]  J. East,et al.  Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection. , 2016, Pathogens and disease.

[26]  Y. Ilan.  Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[27]  Yunzhao Zhao,et al.  Sphingosine kinase 1 inhibition improves lipopolysaccharide/D-galactosamine-induced acute liver failure by inhibiting mitogen-activated protein kinases pathway , 2016, United European gastroenterology journal.

[28]  Liana C. Silva,et al.  Glucosylceramide Reorganizes Cholesterol-Containing Domains in a Fluid Phospholipid Membrane. , 2016, Biophysical journal.

[29]  Y. Ilan.  Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease , 2016, Clinical & translational immunology.

[30]  Ling-Ling Yang,et al.  Inhibition of sphingosine kinase 1 ameliorates acute liver failure by reducing high-mobility group box 1 cytoplasmic translocation in liver cells. , 2015, World journal of gastroenterology.

[31]  D. Campbell.  Control of Regulatory T Cell Migration, Function, and Homeostasis , 2015, The Journal of Immunology.

[32]  Y. Ilan,et al.  Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance. , 2015, World journal of gastroenterology.

[33]  M. Bolli,et al.  Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling. , 2014, Cellular signalling.

[34]  Sarah Spiegel,et al.  Sphingolipid metabolites in inflammatory disease , 2014, Nature.

[35]  S. Pitson,et al.  Roles, regulation and inhibitors of sphingosine kinase 2 , 2013, The FEBS journal.

[36]  A. Snider.  Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease. , 2013, International journal of clinical rheumatology.

[37]  V. Natarajan,et al.  The Roles of Sphingosine Kinase 1 and 2 in Regulating the Metabolome and Survival of Prostate Cancer Cells , 2013, Biomolecules.

[38]  Y. Ilan,et al.  Hepatoprotective effect of DT56a is associated with changes in natural killer T cells and regulatory T cells , 2013, Journal of digestive diseases.

[39]  L. Obeid,et al.  Inhibition of Sphingosine Kinase-2 in a Murine Model of Lupus Nephritis , 2013, PloS one.

[40]  J. Edwards,et al.  Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers , 2012, Front. Oncol..

[41]  S. Marks,et al.  Increased Serum Concentration of Sphingosine-1-phosphate in Juvenile-onset Systemic Lupus Erythematosus , 2012, Journal of Clinical Immunology.

[42]  Man Liu,et al.  Immune mechanisms of Concanavalin A model of autoimmune hepatitis. , 2012, World journal of gastroenterology.

[43]  T. Mosher,et al.  Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase , 2011, Inflammopharmacology.

[44]  M. Gershwin,et al.  CD4+CD25+ Foxp3+ Regulatory T Cells Protect against T Cell-Mediated Fulminant Hepatitis in a TGF-β-Dependent Manner in Mice1 , 2008, The Journal of Immunology.

[45]  R. Proia,et al.  The alliance of sphingosine-1-phosphate and its receptors in immunity , 2008, Nature Reviews Immunology.

[46]  O. Pappo,et al.  Administration of beta-glycolipids overcomes an unfavorable nutritional dependent host milieu: a role for a soy-free diet and natural ligands in intrahepatic CD8+ lymphocyte trapping and NKT cell redistribution. , 2008, International immunopharmacology.

[47]  O. Pappo,et al.  Beta-glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping. , 2008, Journal of lipid research.

[48]  O. Pappo,et al.  Modulation of intracellular machinery by beta-glycolipids is associated with alteration of NKT lipid rafts and amelioration of concanavalin-induced hepatitis. , 2008, Molecular immunology.

[49]  H. Wichers,et al.  Intrahepatic CD8(+) lymphocyte trapping during tolerance induction using mushroom derived formulations: a possible role for liver in tolerance induction. , 2008, World journal of gastroenterology.

[50]  Y. Nishimura,et al.  Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in asthmatic mouse model. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[51]  Y. Ilan,et al.  β-Glycosphingolipids as Immune Modulators , 2008, Journal of immunotoxicology.

[52]  A. Nagler,et al.  Alleviation of Acute and Chronic Graft-Versus-Host Disease in a Murine Model Is Associated with Glucocerebroside-Enhanced Natural Killer T Lymphocyte Plasticity , 2007, Transplantation.

[53]  T. Papadopoulos,et al.  IL‐10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A–induced liver injury in mice , 2007, Hepatology.

[54]  D. Friedman,et al.  β-Glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders , 2006, Gut.

[55]  Masafumi Takahashi,et al.  Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. , 2006, Biochemical and biophysical research communications.

[56]  E. Bonifacio,et al.  Up-Regulation of CD1d Expression Restores the Immunoregulatory Function of NKT Cells and Prevents Autoimmune Diabetes in Nonobese Diabetic Mice1 , 2004, The Journal of Immunology.

[57]  I. Gotsman,et al.  Liver‐associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model , 1999, Hepatology.

[58]  Liana C. Silva,et al.  Ceramide Domains in Health and Disease: A Biophysical Perspective. , 2019, Advances in experimental medicine and biology.

[59]  L. Obeid,et al.  Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis. , 2017, Advances in biological regulation.

[60]  O. Pappo,et al.  Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. , 2009, American journal of physiology. Endocrinology and metabolism.